Delcath Systems Inc (DCTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Delcath Systems Inc (DCTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH13745D
  • |
  • Pages: 64
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloodstream. The company develops formulations for use with the Delcath Hepatic Delivery System (Melphalan/HDS) and to administer high dose chemotherapy to the liver. The company sells its proprietary system to deliver and filter melphalan hydrochloride in Europe under the trade name, Delcath Hepatic Chemosat Delivery System for Melphalan (Chemosat). Delcath is headquartered in New York, the US.

Delcath Systems Inc (DCTH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Delcath Systems Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deal Details 12

Equity Offering 12

Delcath Systems Plans to Raise up to USD100 Million in Public Offering of Securities 12

Delcath Systems Raises USD8.1 Million in Rights Offering of Shares 13

Delcath Systems Plans to Raise up to USD6 Million in Public Offering of Shares 15

Delcath Systems Files Registration Statement for Public Offering of Units for up to USD10 Million 16

Delcath Systems Raises USD5 Million in Public Offering of Units 17

Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 18

Delcath Systems Raises USD1.3 Million in Public Offering Shares and Warrants 19

Delcath Systems Raises USD7 Million in Public Offering of Units 20

Delcath Systems Raises USD3 Million in Public Offering of Shares and Warrants 22

Debt Offering 24

Delcath Systems Raises USD1.7 Million in Private Placement of 8% Notes 24

Delcath Systems Raises USD0.57 Million in Private Placement of 8% Notes Due 2019 25

Delcath Systems Raises USD35 Million in Private Placement of Notes 26

Delcath Systems Inc-Key Competitors 27

Delcath Systems Inc-Key Employees 28

Delcath Systems Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Aug 15, 2018: Delcath announces second quarter fiscal 2018 financial results 30

May 10, 2018: Delcath Announces First Quarter 2018 Financial Results 32

Mar 16, 2018: Delcath Announces 2017 Financial Results 34

Nov 14, 2017: Delcath Announces Third Quarter 2017 Financial Results 37

Aug 08, 2017: Delcath Announces Second Quarter 2017 Financial Results 39

May 09, 2017: Delcath Announces First Quarter 2017 Financial Results 41

Mar 29, 2017: Delcath Announces 2016 Financial Results 43

Corporate Communications 45

Nov 20, 2017: Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder 45

Sep 14, 2017: Delcath Announces Accelerated Listing on OTCQB 46

Sep 13, 2017: Delcath Announces Relisting on OTCQB 47

Product News 48

12/05/2017: Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology 48

09/19/2017: Data on Delcaths CHEMOSAT System Presented at CIRSE Annual Meeting 49

05/16/2018: Delcath's CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases 50

05/14/2018: Delcath's PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 51

02/21/2017: Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy 52

01/18/2017: New Outcomes Data Using Delcaths Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium 53

01/10/2018: Delcath Announces Special Protocol Agreement Modification With FDA 54

Product Approvals 55

Mar 27, 2017: Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma 55

Clinical Trials 56

May 07, 2018: Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma 56

May 03, 2018: Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial 57

Mar 29, 2018: Summary of Recent Published Research on Delcath's PHP Therapy Presented at Society of Surgical Oncology Annual Symposia 58

Feb 02, 2018: Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe 59

Jan 09, 2018: Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology 60

Dec 19, 2017: Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial 61

Feb 22, 2017: Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies 62

Jan 12, 2017: Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64

List of Figures

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Delcath Systems Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Delcath Systems Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Delcath Systems Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10

Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Delcath Systems Plans to Raise up to USD100 Million in Public Offering of Securities 12

Delcath Systems Raises USD8.1 Million in Rights Offering of Shares 13

Delcath Systems Plans to Raise up to USD6 Million in Public Offering of Shares 15

Delcath Systems Files Registration Statement for Public Offering of Units for up to USD10 Million 16

Delcath Systems Raises USD5 Million in Public Offering of Units 17

Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 18

Delcath Systems Raises USD1.3 Million in Public Offering Shares and Warrants 19

Delcath Systems Raises USD7 Million in Public Offering of Units 20

Delcath Systems Raises USD3 Million in Public Offering of Shares and Warrants 22

Delcath Systems Raises USD1.7 Million in Private Placement of 8% Notes 24

Delcath Systems Raises USD0.57 Million in Private Placement of 8% Notes Due 2019 25

Delcath Systems Raises USD35 Million in Private Placement of Notes 26

Delcath Systems Inc, Key Competitors 27

Delcath Systems Inc, Key Employees 28

Delcath Systems Inc, Other Locations 29

Delcath Systems Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Delcath Systems Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com